How California Retailers Are Splitting One A-and-M-Designated License into Two Under the DCC’s Emergency Rule

Since California’s adult-use market opened in 2018, a dual-designated A-and-M retailer has been one licensee for every purpose that matters. The Department of Cannabis Control’s emergency rule of June 4, 2026 has changed that. Now, a retailer holding one license with both an Adult-Use (“A”) and a Medicinal (“M”) designation can hold two separate licenses on the same premises, in two different legal entities, if a short list of conditions is met (DCC-2026-03-E, Final Text). The DCC emergency rule responds to a federal policy shift: on April 28, 2026, the Acting Attorney General’s rescheduling order placed FDA-approved marijuana drug products and marijuana ‘subject to a state medical marijuana license’ in Schedule III and made these operators eligible for DEA registration through an expedited pathway (91 Fed. Reg. 22714). Picking up where my last rescheduling post left off, this post turns to how the June 4 DCC emergency rule operates vis-à-vis the two federal drivers it was designed to unlock: DEA registration and § 280E.

What California Retailers Were Already Doing Before June 4

The June 4 rule was not the first movement toward separation. A licensee could always change a designation via Form 27, and DCC had been streamlining that path since the rescheduling order landed — dropping the local-authorization requirement for changes to M-only or for adding M to an existing A (DCC Federal Rescheduling Resources). As of May 18, 2026, DCC had processed 10 designation changes to M-only and 196 additions of M to an existing A. Those conversions produced dual-designated licensees who could not, under then-existing rules, hold both designations in separate entities. That constraint is what the June 4 rule broke, opening the path for approximately 1,600 licensees on a five-business-day review clock.

What the Emergency Rule Actually Does

The rule amends 4 CCR §§ 15000.1(e) and 15000.2(c) and adds §§ 15000.2(b) and 15023.1 (DCC-2026-03-E, Final Text). The prior § 15000.1(e) prohibited any transfer or assignment of a license “to another person or premises” except as provided in Business and Professions Code § 26050.2 (Cal. Code Regs. tit. 4, § 15000.1). The amended text keeps that rule but adds that “when separate A and M licenses are held by one entity or two related entities having the same ownership and on the same premises, they shall be considered to be one licensee for compliance and enforcement purposes.”

The substantive conditions sit in § 15000.2(b). Two entities may share the premises through separate A and M licenses if they share the same individual owners and designated responsible party, physically separate cannabis goods, keep records assigned to one license or the other, and — the condition doing the most real work in a distress or dispute — are “jointly and severally liable for all obligations, debts, and violations incurred under either license.” Section 15023.1 supplies the mechanics: the designated responsible party submits DCC Form 9207 with the new M-license entity’s formation documents, FEIN, and CDTFA seller’s permit number; DCC acts within five business days; legacy inventory stays under the A-license’s track-and-trace account; the M-license fee is due before inventory can transfer and posts at the next renewal under 4 CCR § 15014; non-compliance grounds suspension or revocation of both licenses.

Why Only Retailers

DCC-2026-03-E is a retail rule. Section 15000.2(b) authorizes separate A and M licenses only for “licensees authorized to engage in retail activities,” and § 15023.1 is drafted expressly for “Licensees Authorized to Engage in Retail.” Microbusinesses qualify only through their retail authorization. Cultivators, manufacturers, and distributors have no analogous path — Form 27 remains their only tool, and it does not bifurcate one license into two entities. The asymmetry is state-law driven, not federal: all three DEA registration categories — dispenser (Form 224) and manufacturer/distributor (Form 225) — share the same expedited 60-day window under 21 CFR § 1301.13(k). The A/M split is a retail problem because retail is where finished cannabis reaches end users under the A or M designation. Cultivators and manufacturers produce cannabis destined for either channel, and § 15000.2(c) handles the distributor side by locking sales of “For Medical Use Only” cannabis to M-designated retailers or M-designated microbusinesses.

The DEA Registration That Drove the Rule

A California retailer holding a combined A and M license could not cleanly enter the Schedule III framework as a single entity. The DEA opened its Medical Marijuana Dispensary Registration Portal on April 29, 2026, and 21 CFR § 1301.13(k)(7) provides that any applicant filing within the expedited window “may engage in the manufacture, distribution, and/or dispensing of marijuana or products containing marijuana for medical purposes in conformity with a state-issued license during the pendency of the application” (DCC Federal Rescheduling Resources). Two features of that language decide the state-side structure. First, the protected activity is only for “medical purposes,” and 21 U.S.C. § 843(a)(4)(A) makes furnishing false information in a DEA application a felony punishable by up to four years’ imprisonment under § 843(d)(1) — an adult-use retailer holding a DEA registration is not federally authorized for its adult-use sales. Second, the protection runs only in “conformity with a state-issued license,” so anything DCC treats as non-compliance compromises the federal safe harbor.

A single-entity retailer selling both A- and M-designated cannabis therefore had a structural federal-law problem the emergency rule solves: the M-entity holds the DEA registration and operates within Schedule III; the A-entity remains outside the federal system. Applicants filing after June 26 fall onto the ordinary registration path with no processing-time commitment and no pendency safe harbor.

Why the Split Matters for Section 280E

DEA registration is not the only federal driver, and for many retailers it is not the most important one. Because IRC § 280E disallows deductions only for trafficking in Schedule I or II controlled substances, rescheduling automatically removes § 280E from qualifying medical activity. Treasury and IRS confirmed on April 23, 2026 that “rescheduling generally removes section 280E as a bar to claiming deductions and credits” (Treasury Press Release SB0471). No DEA registration is required to invoke that relief — the trigger is the M-designation, not the federal registration. But invoking it and being able to defend it on audit are two different things.

Treasury also announced that guidance is expected to clarify how § 280E applies to “businesses with multiple activities,” including “by apportioning expenses” (Treasury Press Release SB0471). A dual-designated retailer selling both A and M cannabis through one license is exactly such a business: the M-side has moved to Schedule III, the A-side has not. Under the pre-split structure, apportionment happens inside one entity, one FEIN, one seller’s permit, one set of books. Under DCC-2026-03-E, the retailer presents two entities, two FEINs, two CDTFA seller’s permits, separately maintained records under § 15000.2(b)(3), and physically segregated inventory under § 15000.2(b)(2). That is the audit-defensible segregation Treasury’s guidance will likely require.

The “Exactly Match” Ownership Requirement

Section 15000.2(b)(1) requires the two entities to share “the same individual owners” and the same designated responsible party. DCC’s compliance hub reads that as requiring ownership to “match exactly,” while the two licenses “cannot share a CDTFA seller’s permit number or FEIN” (DCC Federal Rescheduling Resources). Read against 4 CCR § 15003, which defines “owner” to include both twenty-percent equity holders and any individual “who manages, directs, or controls the operations” (officers, directors, general managers, non-member LLC managers, general partners, nonprofit board members, and trustees of a controlling trust), “match exactly” is not a shareholder-schedule test. The two entities must share their complete § 15003 owner lists, equity holders and officer bench alike. A holding company that spins off an M-license subsidiary with a different CEO or general manager has, in a strict reading, changed the owner list. Multi-store operators are the most exposed, because § 15003(a)(2)(E) sweeps in the roles most likely to differ site-to-site under an integrated corporate structure. Financial interest holders under 4 CCR § 15004 need not match, but every change still triggers § 15023(d)’s 14-day disclosure rule.

The Joint-and-Several Liability Trap

Section 15000.2(b)(4) is the single most consequential provision in the rule and the least discussed in industry coverage. The two entities “shall be jointly and severally liable for all obligations, debts, and violations incurred under either license.” That has no analog in ordinary corporate law: sister entities under a common parent are not, absent contract or veil-piercing, liable for one another’s debts. Section 15000.2(b)(4) makes them liable by regulation, with no carve-out for secured debt, tort claims, or tax.

The consequences run through the whole capital and compliance stack. A lender taking a security interest in the M-entity’s assets alone will find, if the A-entity defaults, the M-entity collateral exposed by state regulatory law; loan documents will need cross-collateralization and cross-default provisions. CDTFA collection tools already reach broadly, and § 15000.2(b)(4) gives CDTFA a state-regulatory argument that unpaid tax on A-license activity is collectible against the M-entity. On the federal side, 21 U.S.C. § 823(g)(1)(D) makes “compliance with applicable State, Federal, or local laws relating to controlled substances” one of five public-interest factors DEA weighs on a dispensing registration, so the A-entity’s compliance record is a risk the M-entity should account for at registration and renewal.

Joint-and-several liability also runs through inventory. Section 15023.1(d) preserves the existing A-license track-and-trace account and requires payment of the M-license fee before any inventory can transfer, so the M-entity opens without inventory it can lawfully sell as its own — a working-capital burden that matters most for retailers splitting primarily for § 280E relief, because the tax arithmetic starts only when the M-entity has its own Schedule III inventory. And because amended § 15000.1(e) treats the two as “one licensee for compliance and enforcement purposes,” § 15023’s 14-day owner-reporting rule cuts across both entities (Cal. Code Regs. tit. 4, § 15023): an M-entity investor triggering § 15003(a)(1) without a matching change on the A-side breaks “exactly match,” and § 15023.1(e) makes the deviation grounds for suspension or revocation of both licenses. DCC’s Disciplinary Guidelines classify unauthorized business modifications under § 15023 as a Tier 3 offense with revocation as the maximum penalty (DCC Disciplinary Guidelines). The rule provides no cure period.

What Careful Drafting Will Look Like

The rule creates a working structure for retailers that already treat medical and adult-use activity as distinct businesses, and a landmine for retailers that treat them as two labels on one book of business. Careful counsel will keep cap tables and officer rosters mirrored by contract; cross-collateralize secured debt and cross-guarantee material contracts, because § 15000.2(b)(4) will get there anyway; build the general ledger and payroll allocations to reflect the two-entity structure from day one, because Treasury’s apportionment guidance will treat books-and-records segregation as the threshold for § 280E relief; and draft the M-entity’s DEA compliance program on the assumption that the A-entity’s regulatory record will follow it into federal registration and renewal.

The rule expires December 2, 2026, and DCC must finalize a certificate of compliance to make it permanent. Whether the permanent version tightens “match exactly,” softens joint-and-several liability, or clarifies the § 15023 cure question will decide how many California retailers can use this structure. For now, the operators moving first are those with clean cap tables and disciplined compliance programs — those who have retained California cannabis regulatory counsel to reconcile the rule with §§ 15003, 15004, 15023, and 21 CFR § 1301.13(k) before submitting Form 9207.

This post is general information about California and federal law and is not legal advice. Cannabis licensing decisions are fact-specific and time-sensitive. If your business is evaluating an A/M split, consult counsel promptly.